Obesity Surgery

, Volume 20, Issue 4, pp 506–508 | Cite as

Long-Term Results of Gastric Bypass Surgery in Morbidly Obese Type 1 Diabetes Patients

  • Leszek CzupryniakEmail author
  • Marcin Wiszniewski
  • Dariusz Szymański
  • Maciej Pawłowski
  • Jerzy Loba
  • Janusz Strzelczyk
Clinical Report



Long-term effects of bariatric surgery in morbidly obese type 1 patients are unknown. Five to eight-year experience in the case series of type 1 diabetes subjects is presented.


Three poorly controlled type 1 diabetes patients, aged 19, 23, and 28 underwent Roux-en-Y gastric bypass surgery.


Their maximum body weight reduction noted during the follow-up was between 27% and 31% of baseline body weight, insulin requirement decreased from 0.6–0.95 to 0.3–0.83 IU/kg, and absolute reduction in HbA1c was 3–4%. Significant improvement in blood pressure, plasma lipid profile, and microalbuminuria was noted.


RYGB surgery in morbidly obese type 1 diabetes patients leads to a significant and maintained weight loss and results in remarkable improvement in blood glucose control and concomitant disorders. Bariatric surgery should be recommended to significantly obese type 1 diabetes patients as a means of reduction of vascular complications risk.


Type 1 diabetes Vascular complications Prevention Morbid obesity Gastric bypass 


Conflict of interest



  1. 1.
    Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;15:CD003641.Google Scholar
  2. 2.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Czupryniak L, Strzelczyk J, Pawłowski M, et al. Mild elevation of fasting plasma glucose is a strong risk factor for postoperative complications in gastric bypass patients. Obes Surg. 2004;14:1393–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Alexandrides TK, Skroubis G, Kalfarentzos F. Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity. Obes Surg. 2007;17:176–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity. 2009;17 Suppl 1:S1–70.PubMedGoogle Scholar
  6. 6.
    de Boer IH, Kestenbaum B, Rue TC, et al. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008;22:1867–73.CrossRefGoogle Scholar
  7. 7.
    Pang TT, Narendran P. Addressing insulin resistance in type 1 diabetes. Diabet Med. 2008;25:1015–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16:94–112.CrossRefPubMedGoogle Scholar
  9. 9.
    Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol. 2008;158:135–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008;24:832–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700.CrossRefPubMedGoogle Scholar
  12. 12.
    Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth Study. Pediatr Dia. 2009. doi: 10.1111/j.1399-5448.2009.00519.x.Google Scholar
  13. 13.
    Pozzilli P, Guglielmi C. Double diabetes: a mixture of type 1 and type 2 diabetes in youth. Endocr Dev. 2009;14:151–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Reinehr T, Schober E, Wiegand S, et al. Holl R; DPV-Wiss Study Group. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child. 2006;91:473–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosenbloom AL, Silverstein JH, Amemiya S, et al. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Type 2 diabetes in the child and adolescent. Pediatric Dia. 2009;10 Suppl 12:17–32.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2010

Authors and Affiliations

  • Leszek Czupryniak
    • 1
    Email author
  • Marcin Wiszniewski
    • 2
  • Dariusz Szymański
    • 2
  • Maciej Pawłowski
    • 1
  • Jerzy Loba
    • 1
  • Janusz Strzelczyk
    • 2
  1. 1.Diabetology and Metabolic Diseases DepartmentBarlicki University Hospital No 1LodzPoland
  2. 2.General and Transplant Surgery DepartmentBarlicki University Hospital No 1, Medical University of LodzLodzPoland

Personalised recommendations